New York, Sept. 30 - Pervasis Therapeutics, Inc. said it completed a $12 million series B financing.
New investor Highland Capital Partners led the round, and founding investors Polaris Venture Partners and Flagship Venture Partners also participated.
"We are excited to work with the Pervasis founding scientists and investors as the company prepares to bring its innovative therapies to market," said Bob Higgins, managing general partner at Highland Capital Partners, in a news release. "With a distinguished team onboard, significant development complete, and the path forward clear, Pervasis is well-poised to emerge as the leader in a transformative new class of therapies."
Higgins will join Pervasis' board of directors.
The Cambridge, Mass.-based company will use proceeds to fund continued clinical development of its first product, a combination device for patients with vascular disease.
Pervasis is focused on creating biologically active vascular technologies to treat significant unmet needs in cardiovascular disease. Its products combine advances in cell biology, drug delivery and biomaterials.
| Issuer: | Pervasis Therapeutics, Inc.
|
| Issue: | Series B financing
|
| Amount: | $12 million
|
| Investors: | Highland Capital Partners (lead), Polaris Venture Partners, Flagship Venture Partners
|
| Announcement date: | Sept. 30
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
